Cite
Coelho T, Ando Y, Benson MD, et al. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L. Neurol Ther. 2021;10(1):375-389doi: 10.1007/s40120-021-00235-6.
Coelho, T., Ando, Y., Benson, M. D., Berk, J. L., Waddington-Cruz, M., Dyck, P. J., Gillmore, J. D., Khella, S. L., Litchy, W. J., Obici, L., Monteiro, C., Tai, L. J., Viney, N. J., Buchele, G., Brambatti, M., Jung, S. W., St L O'Dea, L., Tsimikas, S., Schneider, E., Geary, R. S., Monia, B. P., & Gertz, M. (2021). Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L. Neurology and therapy, 10(1), 375-389. https://doi.org/10.1007/s40120-021-00235-6
Coelho, Teresa, et al. "Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L." Neurology and therapy vol. 10,1 (2021): 375-389. doi: https://doi.org/10.1007/s40120-021-00235-6
Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L. Neurol Ther. 2021 Jun;10(1):375-389. doi: 10.1007/s40120-021-00235-6. Epub 2021 Feb 26. PMID: 33638113; PMCID: PMC8140170.
Copy
Download .nbib